Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD to be featured at B. Riley Securities Healthcare events

Wednesday, May 8, 2024 1 min read
Key Takeaway: Radiopharm Theranostics (RADX) will be featured at upcoming B. Riley Securities Healthcare events. The company has recently received IND approval from the FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, RAD has provided positive updates across four clinical programs, enhancing its profile in the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD is gaining visibility through B. Riley Securities events.
  • Positive clinical updates across multiple programs.
  • Recent IND approval from the FDA for a new study.

Full Press Release Details

• Announcements
• May 8, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• September 5, 2022
• Announcements
• December 9, 2022
• Announcements
• November 27, 2024
• Announcements
• September 30, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What events will RAD be featured at?

RAD will be featured at B. Riley Securities Healthcare events.

What recent approval did RAD receive from the FDA?

RAD received IND approval to initiate a Phase I study targeting B7H3.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic product being developed by RAD.

What updates has RAD provided recently?

RAD has shared positive clinical updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare B7H3 BetaBart FDA IND approval clinical updates
Last updated: May 8, 2024